iFAST Diagnostics specializes in rapid antimicrobial susceptibility testing (AST) to combat antimicrobial resistance (AMR). Their technology utilizes microfluidic impedance chips to measure electrical properties of bacterial cells within Gram-negative blood cultures. This enables clinicians to determine antibiotic susceptibility in under three hours, significantly faster than the 24-72 hour industry standard. By accelerating accurate diagnosis, iFAST facilitates timely prescription of effective treatments, reducing patient deterioration and hospital stays while curbing resistant infection spread. The company holds UKCA certification and collaborates with major healthcare providers.